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My studies focused on identifying cell-extrinsic mechanisms of drug resistance of Acute 
Myeloid Leukemia (AML) in order to develop improved therapies. In Chapter 2, we 
discovered human bone marrow (BM) mesenchymal stromal cells (MSCs) highly express 
the primary retinoid inactivating enzyme, Cytochrome P450 26 (CYP26). CYP26 
protects both APL and non-APL AML cells from the pro-differentiation effects of all-
rans retinoic acid (ATRA). Inhibition of CYP26 rescued ATRA levels and AML cell 
sensitivity in the presence of BM stroma. Our data suggest that stromal CYP26 activity 
creates retinoid low sanctuaries in the BM that protect AML cells from systemic ATRA 
therapy. Inhibiting or bypassing CYP26 provides new opportunities to expand the clinical 
activity of ATRA in both APL and non-APL AML. We also discovered that BM MSCs 
express a wide variety of CYPs and other drug metabolizing enzymes, similar to 
hepatocytes. Importantly, CYP3A4, which is responsible for inactivating half of currently 
available chemotherapeutics, is highly expressed in the BM MSCs and protected 
leukemia stem cells (LSCs) and multiple myeloma (MM) CSCs. Inhibiting CYP3A4 
overcame the stroma’s chemoprotective capacity. In Chapter 3, we found that the 
CYP3A4 and cytidine deaminase (CDA) expression levels of BM MSCs are down- 
regulated by AML cells. More so, AML chemotherapy drugs cytarabine (ara-C), 
daunorubicin and etoposide (VP-16), induce CYP3A4 and CDA levels in MSCs as well 
as increase stromal protective effect. Understanding how CYPs levels vary in AML BM 
during treatment provides a basis for combining a stromal CYP3A4 inhibitor with 
chemotherapy to improve the elimination of minimal residual disease (MRD). These 
studies thus identify mechanisms of differentiation therapy and chemotherapy drug 
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1.1 Bone Marrow Microenvironment 
1.1.1 Overview  
Hematopoietic stem cells (HSCs) are essential to preserve hematological homeostasis and 
regeneration, and are the only cells capable of giving rise to all blood cell lineages [1, 2]. 
The bone marrow (BM) microenvironment is essential for HSCs to maintain lifelong blood 
production, by balancing its self-renewal and differentiation. Within the BM 
microenvironment, HSCs communicate with surrounding cells through cell-cell contacts 
and soluble factors. These interactions are essential to maintain HSCs by regulating their 
quiescence, self-renewal and differentiation [3, 4]. Analogously to normal stem cells, 
cancer stem cells (CSCs) reside in specific niches that maintain their tumor initiation 
capacity and protect them from threats posed by the immune system and chemotherapy [5, 
6].   
 
A better understanding of hematopoiesis and cancer cell biology has resulted in rapid 
therapeutic advances, leading to increased response rates and prolonged survivals. 
However, these advances have not generally translated to more cures. Increasing 
evidence suggests that rare populations of CSCs, characterized for their ability to self-
renew, differentiate and survive chemotherapy, are significant contributors to minimal 
residual disease (MRD) and relapse [7-9]. Research has traditionally focused on cell-
intrinsic mechanisms, such as quiescence or genetic heterogeneity, to understand the 
survival advantage of CSCs during chemotherapy [10]. However, over the past few years, 
the mechanism by which the microenvironment contributes to chemotherapy resistance of 
this malignant population has been an area of active research [11, 12]. Disrupting the 





communication with their niche holds potential for eliminating the malignant clones that 
reside at the top of the cancer hierarchy.    
 
Many patients with AML are able to achieve complete remissions (CRs) with standard 
chemotherapy. However, CRs do not mean cures for most of these patients, and the 
majority will eventually relapse and die of their disease. The cancer stem cell (CSC) 
model provides a reasonable explanation for this gap between remission and cure. The 
current therapies often kill only the differentiated bulk of the cancer, but the more 
resistant CSCs then regenerate the disease. Besides of the important cell intrinsic 
mechanisms of CSC drug resistance, there is much evidence that the BM 
microenvironment also plays an important role in CSC drug resistance. However, the 
mechanisms of BM microenvironment mediated drug resistance were poorly understood.  
 
Definitive evidence for the existence of stem cells was provided first in the hematopoietic 
system, when Till and McCulloch reported the presence of hematopoietic colonies in the 
spleen of irradiated mice after transplantation with BM cells [1]. And it was also in the 
hematopoietic system where the term “stem cell niche” was described for the first time, 
after Schofield found that stem cells from the bone marrow had the ability to reconstitute 
the hematopoietic system indefinitely, while spleen-derived stem cells previously 
reported by Till and McCulloch did not have this ability [13].  He suggested the existence 
of a distinctive niche within the BM essential to maintain a stem cell phenotype, by 
preventing the maturation of these cells. 
 





Analogous to the role of normal stem cells in maintaining lifelong tissue homeostasis, 
evidence gathered over the past two decades suggests that a rare population of cancer 
cells with the ability to self-renew and differentiate is responsible for giving rise and 
propagating cancer [7-9]. Strong support for the CSC model was provided by Lapidot et 
al who observed that only a rare subset of leukemia cells, compromising less than 0.01% 
of the total population, were able to engraft and produce acute myeloid leukemia (AML) 
in mice [8]. Later studies further supported this hypothesis in AML [14, 15], which 
appears to organized in a hierarchical manner similar to normal hematopoiesis, with 
primitive CD34+ CD38- stem cells as the target of malignant transformation but the bulk 
of disease representing differentiated progeny. As such, leukemia stem cells (LSCs) can 
be considered true stem cells with the ability to: 1) differentiate into the bulk 
differentiated leukemia cells; and 2) self-renewal as evidenced by their ability to engraft 
immunodeficient mice upon serial transplantation.  
 
Although LSCs were initially described in AML as a relatively homogenous CD34+ 
CD38- population, it is now known that they are phenotypically as well as genetically 
heterogeneous [16, 17]. With a few exceptions, such as TKIs inhibitors in CML, this 
cellular and molecular heterogeneity has complicated the development of targeted 
therapies for specific mutations or markers. For this reason, treatment of hematologic 
malignancies has relied on the so-called “traditional chemotherapy” which targets rapid 
proliferative cells. These classic cytotoxic agents often leave behind CSCs, which unlike 
the bulk of the malignant cells but similar to normal HSCs, are characterized by a 
dormant or quiescent state in part induced by the microenvironment [11, 12]. Thus, better 





understanding the biology of the CSCs microenvironment could allow novel anti-cancer 
therapies aimed at disrupting its influence on CSCs.  
 
1.1.2 The hematopoietic stem cell niche 
Bone marrow is a complex organ containing many different hematopoietic and non-
hematopoietic cell types. Bone marrow is surrounded by a shell of vascularized and 
innervated bone (Figure 1.1). The HSCs reside primarily within bone marrow during 
adulthood. The hematopoietic niche can be broadly subdivided into a perivascular area, 
located close to the central vein of the BM, and an endosteal area, located close to the 
internal lining of the bone. Both areas harbor a variety of stromal cells, including 
osteoblasts, fibroblasts, adipocytes, endothelial cells and mesenchymal stem cells (MSCs) 
[3, 4] (Figure 1.2). 
 
 






Figure 1.1. Bone marrow anatomy 
a. Minute projections of bone (trabeculae) are found throughout the metaphysis such that 
many cells in this region are close to bone surface. b. The interface of bone and bone 
marrow is known as the endosteum, which is covered by bone-lining cells that include 
bone-forming osteoblasts and bone-resorbing osteoclasts. Arteries carry oxygen, nutrients, 
and growth factors into the bone marrow, before feeding into sinusoids, which coalesce 
as a central sinus to form the venous circulation. Sinusoids are specialized venuoles that 
form a reticular network of fenestrated vessels that allow cells to pass in and out of 
circulation. There is a particularly rich supply of arterioles as well as sinusoids near the 
endosteum. (Modified from Morrison, S.J. and Scadden, D.T. The bone marrow niche for 
haematopoietic stem cells. Nature. 2014; 505: 327–334) 






Figure 1.2. Haematopoietic stem cells (HSCs) and restricted haematopoietic 
progenitors occupy distinct niches in the bone marrow. (from Morrison, S.J. and 















The majority of HSCs have a perivascular location, and 60-67% are located within 20 µm 
of the sinusoidal endothelium, most of them in the endosteal region of the bone [18-21]. 
Different cell types and the cytokines, adhesion molecules or extracellular matrix proteins 
are associated with this regional localization. MSCs, defined by their trilineage 
(adipocytes, osteo- and chondro-lineage) differentiation potential and expression of 
Nestin and LepR, are in close contact with sinusoidal endothelium [22, 23]. Moreover, 
MSCs have the highest expression of genes associated with HSCs maintenance, including 
CXCL12, stem cell factor (SCF or kit ligand) or angiopoietin-1, and their depletion 
significantly compromises hematopoiesis [21].  Endothelial cells (ECs) surrounding 
arterioles and sinusoids are also part of the BM niche. Similar to the role of MSCs, 
expression of SCF and CXCL12 by ECs promotes HSCs maintenance and self-renewal 
[19, 24]. 
 
Osteoblasts were the first component of the BM niche found to regulate hematopoiesis. 
Initial studies showed that osteoblasts supported the growth of HSCs in vitro [25, 26], 
followed by in vivo experiments demonstrating that osteoblastic activation or expansion 
resulted in increased numbers of HSCs and increased survival of irradiated mice after 
BM transplantation. Further, depletion of osteoblasts was associated with severe loss of 
HSCs from the BM, with extra-medullary hematopoiesis [27-29].  
 
Recent studies have suggested that not only stromal but also hematopoietic components 
are essential for HSCs maintenance. HSCs are non-randomly located close to 
megakaryocytes, and their depletion results in loss of HSCs quiescence, compromising 





repopulation ability [30, 31].  In addition, macrophages are essential for erythropoiesis 
and recovery from hemolytic anemia and acute blood loss [32].  
 
In summary, different cellular components of the BM niche may have either direct or 
indirect roles in hematopoiesis. Based on studies demonstrating that the majority of HSCs 
localize close to blood vessels, and that deletion of HSCs-retaining genes from ECs and 
MSCs, but not from osteoblasts, compromises hematopoietic recovery after 
transplantation, some have concluded that the niche is perivascular [19, 21].  
 
1.1.3 Leukemia stem cell (LSC) niche   
The facts that BM is a common metastatic site for solid tumors, and that leukemia cells 
migrate early to bone marrow spaces throughout the body, before metastasizing to other 
tissues, suggests that the BM provides a unique niche for malignant cells.  Moreover, the 
BM serves as sanctuary for MRD, not only in hematologic malignancies, but also in solid 
tumors [11, 33, 34]. When examined in long bones, such as the femur, engraftment of 
LSCs concentrates in the endosteal regions, while their differentiated progeny expands, 
migrates and packs in the central region of the bone marrow [35]. After treatment with 
chemotherapy, apoptosis is only evident in the central BM cavity, while quiescent 
leukemic cells within the endosteum are spared, eventually causing relapse [36]. 
 
Many of the mechanisms by which the BM microenvironment maintains HSCs are co-
opted by CSCs to perpetuate cancer, promoting a balance of self-renewal, differentiation 
and proliferation. Within the endosteal region, leukemia cells bind to sinusoidal 





perivascular cells in an identical fashion to normal HSCs [37, 38]. This interaction is 
facilitated by perivascular SCF-1 (also called CXCL12), which binds to CXCR4 on 
malignant cells. LSCs appear to be selectively beneficiated by these physical contacts, 
since expression of CXCR4 on CD34+ leukemic blasts, but not on the bulk of leukemia 
cells, is correlated with worse prognosis [39]. 
 
Similarly to CXCR4-CXCL12, the interaction between leukemic VLA-4 and stromal 
fibronectin is also critical for maintaining LSCs [40]. Consistent with this, patients whose 
AML blasts are negative for this adhesion molecule have significantly increased survival 
compared to VLA-4 positive patients [41]. Multiple myeloma (MM) cells also employ 
adhesion molecules to home and survive within the bone marrow niche [42, 43].   
 
Therapeutic strategies to overcome microenvironmental chemoprotection have focused 
on displacement of malignant cells from the BM niche by targeting adhesion molecules 
or chemokines. Preclinical studies have demonstrated that inhibition of the CXCR4-
CXCR12 interaction impairs engraftment of leukemic cells, which remain in the 
circulation instead of homing to the BM [44-46]. Similarly, blocking VLA-4 results in a 
dramatic increase of AML cells in the peripheral circulation, and combination of this 
antibody with ara-C increases improved AML kill in vitro [40]. Expression of CD44, 
another adhesion molecule expressed on malignant cells, is also associated with 
maintenance of a CSC phenotype and drug resistance, and its inhibition reduces the size 
of the CSC compartment and enhances chemotherapy efficacy in preclinical models of 
AML, CML and MM [47-49]. However, clinical benefit from mobilizing cancer cells 





from the bone marrow has not been demonstrated in the clinic. Thus, the molecular 




1.2 Cytochrome P450 Enzymes (CYPs) and drug metabolism 
CYPs are one of the most important enzyme families involved in the metabolism of 
xenobiotics. CYPs comprise many isoforms, which catalyze a wide variety of reactions. 
Five of the isoforms, 1A2, 2C9, 2C19, 2D6 and 3A4, metabolize about 90% of the 
marketed drug compounds [50]. Most CYPs are expressed in the liver, including 
CYP3A4, which as the most abundant in human liver accounts for about 30% of total 
hepatic CYPs [51]. CYPs are also present in nearly all tissues, especially those exposed 
to outside foreign toxins, such as the small intestine, kidney, and lung. 
 
CYP expression has also been found in a variety of human tumors, including the bladder, 
breast, colon, esophagus, kidney, lung, ovary, prostate, stomach [52, 53].  The CYPs are 
important for both cytotoxic bioactivation, as well as drug metabolism. CYP3A4 plays an 
important role in the metabolism of many anticancer agents, including the topoisomerase 
inhibitor etoposide, which is one of the most important agents in the treatment of AML 
[54], the taxanes paclitaxel and docetaxel, which are used in the treatment of several 
tumor types including breast, ovarian, head & neck and lung cancer [55, 56], and 
irinotecan, an important drug in colorectal cancer treatment [57].  
 





1.2.1 Retinoid acid and CYP26 
Vitamin A (retinol) plays a critical role regulating the differentiation, growth, and 
migration of many cell types. Classically, the term vitamin A is used to describe retinol 
and retinyl esters (Figure 1.3), including retinyl palmitate, which are the main dietary 
forms of vitamin A obtained from animal products [58, 59]. However, retinol and retinyl 
esters require oxidation by several enzymes to form the biologically active metabolite, 
retinoic acid (RA), the main compound responsible for the biological activity of vitamin 
A. 
 
The retinoid pathway is summarized in Figure 1.4. The two naturally-occurring isomers 
of RA, all-trans-RA (ATRA) and 9-cis-RA, are produced by tissue-specific metabolism 
of Vitamin A (retinol) via intracellular alcohol dehydrogenase (ADH) and aldehyde 
dehydrogenase (ALDH1) [60]. The biologic effects of RA are mediated by binding to 
two families of nuclear hormone receptors, the RA receptor (RAR) and the retinoid X 
receptor (RXR) families [61]. Each family consists of three isotypes (α, β, and γ) that 
function as RAR/RXR heterodimers.  
 
The inactivation of ATRA is predominantly by cytochrome P450 family 26 enzymes 
(CYP26) [62], while some other CYPs including human CYP3A4, CYP2C8 and rat 
CYP2C22 also play a lesser role in this process [63-65]. It is notable that, the affinity of 
ATRA to CYP26 is about 1000- fold higher than it to other CYPs, and the overall 
intrinsic clearance of ATRA by CYP26 enzymes is 1000- to 10,000-fold higher than 
other CYPs [66]. Thus, even in tissues such as the human liver with high expression 





levels of CYP3A4 and CYP2C8, the CYP26s, even are expressed at low levels, are still 
the main contributors to ATRA clearance [62, 66, 67]. CYP-mediated inactivation of 
ATRA is through oxidization at the four-position of the β-ionone ring of ATRA and 
generate 4-OH-RA. The CYPs can also generate several other metabolites from ATRA, 
including 18-OH-RA and 16-OH-RA [67, 68].  
 
CYP26 is a family of three highly conserved isoenzymes, CYP26A1, CYP26B1, and 
CYP26C1. They only share 40-50% sequence similarity in any species [62]. CYP26A1 
and CYP26B1 are the primary members, inactivating both vitamin A and RA; CYP26B1 
is the most highly conserved among these three [62, 69].  
 
CYP26A1 and CYP26B1 mRNA and protein are found in multiple extrahepatic human 
tissues [68, 70]. The RA concentrations in certain tissues are determined by RA synthesis 
and clearance locally, instead of the systemic RA concentrations. CYP26 has been shown 
to establish a barrier for RA delivery from circulation to specific organs, such as the 
testes, pancreas, and spleen [71-73]. Therefore, the extrahepatic expression and activity 
of CYP26 enzymes in specific tissues and cell types play critically important roles in 
tissue-specific RA regulation and defining the relationship between RA and biological 
outcomes in certain tissues.  
 
 







Figure 1.3. Chemical structures of retinyl palmitate, retinol, retinaldehyde, and the 
retinoic acid isomers and metabolites. (from Stevison, F et al. Role of Retinoic Acid-















Figure 1.4. Retinoid pathway. Vitamin A (retinol) is metabolized to retinoic acid (RA) 
via alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH1). Vitamin A 














1.2.2 CYP3A4 and anticancer drugs 
CYP3A4 is involved in the metabolic clearance of most commonly used anticancer drugs, 
including: the taxanes, docetaxel and paclitaxel; the topoisomerase I inhibitors, irinotecan 
and topotecan; the topoisomerase II inhibitors, etoposide and teniposide; the vinca 
alkaloids, vincristine, vinblastine, vindesine and vinorelbine; hormonal therapies 
including exemestane, tamoxifen, fulvestrant and toremifene; and newer molecular 
targeted agents such as gefitinib and imatinib (Table 1) [74, 75]. In the context of cancer 
chemotherapy, most of the drugs have considerable dose-related toxicity. Therefore, 
relatively small differences in the disposition of anticancer drugs in local tissues can lead 
to major differences in both toxicity and efficacy. Understanding the mechanism of the 
anticancer drugs metabolism and drug resistance is very important to improving patient 
outcomes.  



















1.3    Regulation of HSCs fate by the BM microenvironment’s control of RA 
Early observations during the nineteenth century recognized that anemia often occurred 
in individuals with night blindness, unknowingly establishing the first association 
between retinoic acid (RA) and hematopoiesis [76]. Definitive evidence emerged almost 
100 years ago, when it was noted that vitamin A-deficient rats displayed a reduction in 
hematopoietic cells in the BM [77]. Subsequent clinical studies demonstrated that vitamin 
A supplementation improved anemia and reduced susceptibility to infections in children. 
More recently, studies showing the ability of RA to differentiate promyelocytes [78, 79], 
together with the dramatic clinical response to ATRA of patients with APL [80-82], 
suggested a role for RA in myeloid differentiation. Despite these established associations, 
the exact function of the RA pathway in HSC regulation remained unclear, and studies 
have shown contradictory results, with data showing that both, inhibition or stimulation 
of the RA maintains HSC [83-85].   
 
Previously, our group compared genome-wide expression data between human HSCs 
(CD34+ CD38−) and hematopoietic progenitor cells (HPCs) (CD34+ CD38+), to 
investigate molecular pathways associated with HSC self-renewal and differentiation.  
[86]. This analysis demonstrated that the RA pathway is differentially regulated in these 
two compartments. Although HSCs highly express the upstream components of the RA 
pathway, including RARα and ALDH1A1, the downstream targets were absent. On the 
other hand, HPCs show an active RA downstream pathway, with strong expression of its 
target genes. Therefore, despite being able to respond to RA, quiescent HSCs appear to 
lack the appropriate signal; when the signal is provided, the pathway is promptly 





activated and HSCs differentiate to become HPCs. These data suggest that HSCs are 
intrinsically programmed to respond to RA and differentiate, but somehow are prevented 
from doing so within the BM niche.  
 
A role for the microenvironment’s regulation of RA in stem-cell fate has been described 
in a different system: the embryonic gonad [87]. Whether germ cells develop as oocytes 
or spermatogonia depends on the time at which they enter meiosis. In both sexes, germ 
cells are programmed to enter meiosis and become oocytes during the embryonic period 
in response to RA produced by the mesonephroi. However, in the embryonic testis, RA is 
inactivated by CYP26B1 expressed in Sertoli cells, preventing meiosis entry until after 
birth, at which time germ cells become spermatogonia. Thus, germ-cells are intrinsically 
programmed to become oocytes, unless prevented from doing so by the 
microenvironment’s regulation of RA.  
 
Similar to its role in germ cell biology, our group demonstrated that the 
microenvironment’s regulation of RA is essential to determine the fate of HSCs. 
Consistent with this, when HSCs are removed from their niche, they rapidly differentiate, 
acquire a HPC phenotype (CD34+ CD38+) and loss their ability to self-renew [86, 88]. 
However, inhibition of RA signaling allows not only HSC maintenance but even 
expansion, as determined by the number of phenotypic CD34+ CD38- in culture, their 
progenitor output (CFU-Cs) and their ability to form cobblestones after 8 weeks of co-
culture with stroma cells. Most importantly, suppression of RA signaling expands 
functional HSC able to self-renew and differentiate, as evidenced by increased 
























Figure 1.5. Working model of retinoid signaling in the stem-cell niche. Retinoids are 
present in plasma at nanomolar (RA) to micromolar (vitamin A) concentrations (28). 
CYP26 enzymes present in the bone marrow stroma oxidize both RA and vitamin A to 
their inactive 4-oxo-congeners. Accordingly, the stem-cell niche represents a retinoid-low 
“sanctuary” that promotes HSC quiescence, maintenance, and self-renewal. (from Ghiaur, 
G et al. Regulation of human hematopoietic stem cell self-renewal by the 











It has been known for long that bone marrow stroma cells have the ability to maintain 
HSCs in culture [88, 89]. Our group discovered that analogous to Sertoli cells, the BM 
niche regulates HSCs fate by control of RA signaling [86]. In the presence of BM MSCs, 
HSCs maintain their self-renewal and multilineage reconstitution capacity for several 
weeks. However, when CYP26 in blocked, and BM MSCs loss their ability to inactivate 
RA, HSCs rapidly differentiate. This high sensitivity of HSCs to local changes in RA 
concentration can be explained by their constitutive expression of the upstream RA 
pathway components, including ALDH1A and RARα. Consequently, small changes in 
local RA induce a rapid response in HSCs. This study suggests that local control of RA 
levels by the BM niche is essential to the maintenance of HSCs. More importantly, it 


















1.4    Significances of this thesis study 
As outlined above, CYP enzymes have been implicated in drug metabolism and HSCs 
maintenance in the BM. It is particularly interesting to study the role of CYP26 and 
CYP3A4 plays in the BM microenvironment of hematological disorders, when there is 
presence of therapeutic drugs. In Chapter 2, we showed the expression of CYP26 in the 
MSCs in human BM confers AML cells cell-extrinsic resistance to RA treatment, 
protecting AML cells from differentiation. This resistance was reversed when CYP26 
inhibitor was applied to the MSCs. These results drew attention to CYP26 in the MSCs as 
a possible therapeutic target to improve response of AML patients to RA. In Chapter 3, 
we investigated the changes of CYP3A4 and some other chemotherapy drug 
metabolizing enzyme along with chemotherapy, and found the expression level of 
CYP3A4 and protection to AML cells of MSCs is induced by the commonly used 
chemotherapy drugs in AML patients. Further, this protection effect is blocked by 
CYP3A4 inhibitor. Our results suggest that the chemotherapy drugs given to AML 
patients make the BM microenvironment a more drug resistant one. It suggests potential 
therapeutic windows for CYP3A4 targeting agents in clinical studies testing these agents 
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2.1    Abstract 
Differentiation therapy with all-trans retinoic acid (atRA) has markedly improved 
outcome in acute promyelocytic leukemia (APL) but has had little clinical impact in other 
AML subtypes. Cell intrinsic mechanisms of resistance have been previously reported, 
yet the majority of AML blasts are sensitive to atRA in vitro. Even in APL, single agent 
atRA induces remission without cure. The microenvironment expression of cytochrome 
P450 (CYP)26, a retinoid-metabolizing enzyme was shown to determine normal 
hematopoietic stem cell fate. Accordingly, we hypothesized that the bone marrow (BM) 
microenvironment is responsible for difference between in vitro sensitivity and in vivo 
resistance of AML to atRA-induced differentiation. We observed that the pro-
differentiation effects of atRA on APL and non-APL AML cells as well as on leukemia 
stem cells from clinical specimens were blocked by BM stroma. In addition, BM stroma 
produced a precipitous drop in atRA levels. Inhibition of CYP26 rescued atRA levels and 
AML cell sensitivity in the presence of stroma. Our data suggest that stromal CYP26 
activity creates retinoid low sanctuaries in the BM that protect AML cells from systemic 
atRA therapy. Inhibition of CYP26 provides new opportunities to expand the clinical 










2.2    Introduction  
Acute myeloid leukemia (AML) is characterized by impaired differentiation and 
uncontrolled proliferation with subsequent accumulation of immature cells (blasts). Even 
though the treatment results in AML have improved over the past 30 years, more than 50% 
of young adults and 90% of older patients die of their disease [1]. Advances in the 
treatment of one AML subtype, acute promyelocytic leukemia (APL), raised hopes that 
all-trans retinoic acid (atRA)-based therapies might improve outcomes in other AML 
subtypes. In APL, the C-terminus of retinoic acid receptor α (RARα) on chromosome 17 
is most often fused with N-terminus of promyelocytic leukemia protein (PML) on 
chromosome 15 [2]. The resultant fusion protein, PML-RARα has a dominant negative 
effect on retinoic acid signaling and blocks differentiation by recruiting abnormal 
transcription factors and histone-modifying enzymes to critical genes. atRA when used at 
pharmacological concentrations is able to bind PML-RARα and overcome its inhibitory 
effects, thus allowing transcription of target genes. APL progenitors exposed to atRA in 
vitro or during clinical treatment will continue their differentiation program into 
neutrophil which eventually senesce. 
 
The introduction of atRA in western medicine clinical protocols in 1980’s changed the 
face of APL from one of the most malignant types of AML to the most curable [3]. 
Although the PML-RARα translocation appears to enhance the sensitivity of APL to 
atRA and several intrinsic mechanisms of atRA resistance have been identified, including 
overexpression of Tal1, expression of PRAME as well as epigenetic silencing or 




sensitive to atRA in vitro [4, 8-12]. Several clinical trials have even suggested a clinical 
benefit for atRA in at least some subtypes of AML [13-15], although most trials have not 
confirmed these results [16-18]. It is unclear why atRA has activity against non-APL 
AML in vitro, but limited clinical activity. Moreover, atRA as a single agent complete 
remissions (CRs) in APL patients, but all patients eventually relapse [19] with a median 
duration of CR of about 5 months [20]. Thus even in APL there exists minimal residual 
disease (MRD) that remains resistant to atRA therapy [19]. While combinations of atRA 
with chemotherapy or arsenic trioxide eliminates MRD in APL and produces cures [21], 
understanding the mechanism responsible for persistence of MRD in APL patients treated 
with atRA monotherapy may have important implications for expanding atRA-based 
therapies to non-APL AML. 
 
RA’s precursor, vitamin A (retinol), plays unique roles in mammalian ontogeny and 
homeostasis across multiple cellular systems [22]. Since both RA deficiency as well as 
excess has deleterious effects, some incompatible with life, organisms have developed 
feedback mechanisms to control retinoid levels. Thus, tissue levels of RA reflect the 
balance between biosynthesis from vitamin A and inactivation, mostly via cytochrome 
P450 (CYP) 26 family. While hepatic CYP26 plays an important role in maintaining 
systemic retinoid homeostasis [23], recent reports have also implicated these enzymes in 
local control of RA signaling in the microenvironment. In fetal gonads, Sertoli cell 
expression of CYP26B1 determines the fate of the germ cells through modulating atRA 
bioavailability [24]. We recently found that the bone marrow (BM) microenvironment 




physiological retinoid-induced differentiation and promotes their self-renewal [25]. 
 
Here we evaluate if stromal CYP26 also protects leukemia cells from pharmacological 
levels of atRA. We found that BM stroma degraded pharmacological concentrations of 
atRA, rendering even sensitive APL cells resistant to atRA. Moreover, non-APL 
leukemia cells were also highly sensitive to atRA treatment in the absence of BM stroma, 
but became resistant in stromal co-culture conditions; inhibition of CYP26 reversed the 



















2.3     Materials and Methods 
2.3.1 Cell lines 
The human APL cell line NB4 [26] was cultured in RPMI 1640 (Gibco, Rockville, MD, 
USA) with 2 mM L-glutamine (Life Technologies), 100 μg/mL penicillin-streptomycin 
(Gibco), and 10% fetal calf serum (FCS) (Sigma-Aldrich). The M2 AML cells Kasumi-1 
[27] were cultured in RPMI 1640 + 20%FCS and the NPM1 mutated OCI/AML3 cells 
were cultured in minimum essential media (α-MEM) (Corning Cellgro) with 2 mM L-
glutamine, 50 μg/mL penicillinstreptomycin, and 20% FCS. The mouse stroma OP9 cells 
were cultured in α-MEM + 20% FCS. CD34+CD38- cells were isolated from the cell 
lines as previously described. Briefly, the cells were labeled with monoclonal 
phycoerythrin (PE)-conjugated mouse anti-human CD34 IgG1, and allophycocyanin 
(APC)-conjugated mouse anti-human CD38 (all antibodies purchased from BD 
Biosciences, San Jose, CA, USA). 
 
2.3.2 Isolation of CD34+CD38-ALDHint leukemia stem cells 
Clinical bone marrow samples were obtained from patients with newly-diagnosed t(8;21) 
CBF AML granting informed consent as approved by the Johns Hopkins Medical 
Institutes' Institutional Review Board. The Johns Hopkins Institutional Review Board has 
approved these studies. CD34+ cells were isolated as we have previously describe [25, 
28]. Briefly, mononuclear cells will be isolated from fresh samples by Ficoll-Paque (GE 
Healthcare Life Sciences, Piscataway, NJ, density = 1.077) centrifugation. CD34+ cells 
were selected by MiltenyiBiotec (Auburn, CA, USA) microbeads (binding the class II 




further use. The thawed CD34+ cells were labeled with CD34 and CD38 as described 
above, and then stained with Aldefluor (Aldagen, Durham, NC) per manufacturer's 
guidelines. The CD34+CD38-ALDHint cells were then isolated using a FACSAria (BD 
Biosciences), and cultured in RPMI1640 supplemented with 10% FBS (Sigma-Aldrich), 
100 μg/mL penicillin-streptomycin (P/S; Sigma), and growth factors [thrombopoietin 20 
ng/mL, Stem Cell Factor 100 ng/mL, and Flt3 ligand 100 ng/mL (TSF) (all growth 
factors and cytokines are from Amgen)], and incubated at 37°C. 
 
2.3.3 Isolation of primary bone marrow stroma 
Primary bone marrow stroma cells were derived from normal bone marrow donors 
granting informed consent as approved by the Johns Hopkins Medical Institutes' 
Institutional Review Board, as we have previously described [25]. Briefly, mononuclear 
cells isolated from bone marrow of normal volunteers were cultured in FBMD1 media 
[IMDM media (Gibco) supplemented with 15% FBS (Sigma-Aldrich), 5% Horse serum 
(Sigma-Aldrich), 100 μg/mL penicillin-streptomycin (Gibco), and 10
-4
M β 
mercaptoethanol (Sigma-Aldrich)] [29] at 33°C in 5%CO2 overnight. The next day, 
media and cells in suspension were removed and the attached cells were washed twice 
with phosphate-buffered saline (PBS) (Gibco), fresh FBMD1 media was added to the 
flask and they were placed back 33°C in 5%CO2. Half of the media was replaced weekly 
until an adherent monolayer has formed. At that time, the cells were dissociated using 
Trypsin (Gibco) and they were either used for further experiments or cryopreserved. The 
passage number of the cells was recorded with original cells labeled as P1. Experiments 





2.3.4 Co-culture system 
For co-culture conditions, 24-well plates (Sigma) were coated with 0.1% Gelatin (Sigma) 
in PBS for 30 min. at 37°C. Gelatin solution was removed and stroma cells were seeded 
at a density of 5x10
4
 cells/well and cultured until a confluent monolayer was obtained. 
Subsequently, 2.5x10
4
 NB4, and OCI/AML3 cells and 5x104 Kasumi-1 cells and primary 
patient LSCs were plated per well. The cultures were treated with or without 10
-7
MRA 
(for NB4 cells) or 10
-6
M RA (for all other AML cells) as well as 10
-6
MR115866 (CYP26 
inhibitor—generously supplied by Johnson & Johnson, R&D) for 72h. 
 
2.3.5 Colony forming unit (CFU-C) 
Clonogenic growth of AML cell lines was evaluated as we previously described [30, 31]. 
Briefly, previously treated cells were removed from the plate and washed with PBS to 
remove the respective drug. Cells were then counted using Trypan blue and plated 1 mL 
1.2% methylcellulose (Sigma-Aldrich), 30% bovine serum albumin (BSA) (Sigma-
Aldrich), 10
-4
 M β-mercaptoethanol (Sigma-Aldrich), and 2 mM L-glutamine (Gibco). 
Samples were plated in triplicate onto 35-mm
2
 tissue culture dishes and incubated in a 
humidified atmosphere at 37°C and 5% CO2. Colonies consisting of more than 40 cells 
were scored at 5–10 days using an inverted microscope. 
 
2.3.6 Flow cytometry 
The cell lines and clinical AML samples were analyzed for expression of cell surface 




washed with PBS containing 0.2% BSA and stained with the following antibodies for 30 
min at 4°C: phycoerythrin (PE)-conjugated mouse anti-human CD11b IgG1, fluorescein 
isothiocyanate (FITC)-conjugated mouse anti-human CD15 IgM antibodies, FITC-
conjugated mouse anti-human CD34 IgG1, PE-conjugated mouse anti-human CD38 
IgG2α, and allophycocyanin (APC)-conjugated mouse anti-human CD45 IgG2β 
antibodies or their respective isotype controls. All antibodies were purchased from BD 
Biosciences. Cells will be then washed to remove unbound antibody, and evaluated using 
a FACS Calibur (BD Biosciences) with a minimum acquisition of 10,000 events. 
 
2.3.7 Retinoic acid quantification 
Culture media (RPMI+10%FCS), supplemented with 10-6MatRA was incubated at 37°C, 
5% CO2 humidified tissue culture incubator in the presence or absence of OP-9 bone 
marrow stroma with or without 10
-6
MR115866. Media was harvested after 0h, 2h, 8h and 
24h, was spun down to eliminate any potential cellular debris and was frozen and stored 
at -80°C until analysis. For analysis, media was extracted with two step liquid-liquid 
extraction as previously described [32]. RA isomers were quantified using LC-MS/MS on 
a AB Sciex 5500 QTRAP in MRM mode using APCI in positive ion mode as previously 
described [32, 33]. 
 
2.3.8 Statistical analysis 
Statistical analysis was performed by using two-tail unpaired student t test to compare the 






2.4     Results 
2.4.1   Stromal CYP26 prevents atRA-induced differentiation of APL cells 
It is well documented that atRA differentiates NB4 APL cells with subsequent decreased 
cellular expansion (S1A Fig), cell cycle arrest (S1B Fig), up-regulation of differentiation 
markers (S1C Fig), decreased blasts (S1D and S1E Fig) and clonogenic loss (S1F Fig). 
We recently showed that BM mesenchymal stroma protects normal HSCs from atRA-
mediated differentiation through the expression of CYP26, the major mechanism of 
retinoid inactivation [25]. NB4 co-cultures with the mouse BM stromal line OP9 
similarly blocked atRA (10
-7
MatRA for 72h) mediated induction of CD11b expression 
and clonogenic loss (Fig 1A and 1B). Inhibition of CYP26 activity via R115866 restored 
atRA-induced up regulation of CD11b and inhibition of clonogenic activity. The addition 
of the CYP26 inhibitor in the absence of stroma had no effect on atRA-induced 
differentiation (data not shown). Primary human BM stroma also protected against atRA-
induced differentiation of NB4 cells. Low passage (<P3) human primary BM stromal 
cultures from four normal volunteers were co-cultured with NB4 APL cells and atRA. 
As with the OP9 stromal cells, primary stroma blocked atRA-induced differentiation that 
was rescued by CYP26 inhibition (Fig 1C and 1D). Consistent with the lack of direct 
cytotoxic effects of ATRA on APL cells, exposure of these cells to retinoids for 72h in all 








Supplementary Fig 2.1. Effects of ATRA on NB4 APL cells. A) Cellular expansion of 
NB4 APL cells in the presence of 10
-7
M ATRA. ATRA treated cells (triangles) expand 
3.4±0.5 fold by Day (D)3 of cultures compared to 4±0.3 fold in control culture (p = 0.14). 




compared to 32.7±1.3 in control cultures (p<0.01). Data represent mean ± SEM of three 
independent experiments. B) Cell cycle analysis of NB4 APL cells treated with ATRA 
for 6 days. One representative experiment from three with similar results show increased 
cells in G0/G1 phases of cell cycle upon treatment with ATRA. C) Expression CD11b, a 
differentiation marker of NB4 APL cells. Upon culture in the presence of ATRA for 72h 
the mean fluorescence intensity (MFI) of CD11b expression of NB4 cells was 3.05±0.48 
fold higher compared to control cultures. Data represent mean ±SEM of three 
independent experiments, p = 0.01. D) Effects of prolonged ATRA treatment on 
morphologically defined NB4 APL blasts. ATRA treated cultures have 24.2%±3.8% 
blasts at D6 compared to 44.5%±7.1% in control cultures. Data represent mean ± STD of 
four independent experiments, p<0.01.E) Effects of ATRA treatment for 6 days on cell 
size (indicated by Forward Scatter) and cytoplasmic complexity (indicated by right angle 
Side Scatter). Compared to control (red circle), ATRA treated cultures contain a 
population of cells (blue oval) that are relatively smaller and have increased cytoplasmic 
complexity. One representative experiment from three with similar results. F) Effects of 
10
-7
M ATRA on the clonogenic activity of NB4 APL cells. Treatment with ATRA for 
72h results in 49.1%±8.9% clonogenic recovery from control cultures. Data represent 







Fig 2.1. Effects of BM stroma on atRA-induced differentiation of APL cells. Effects 
of 10-7M ATRA±10-6M R115866 for 72h on the (A) expression of CD11b and (B) 
clonogenic growth of NB4 APL cells in the presence of OP9 BM stroma. Data represent 
mean ± SEM of three independent experiments. Effects of 10-7M atRA ± 10-6M 
R115866 for 72 hours on the (C) expression of CD11b and (D) clonogenic growth of 
NB4 APL cells in the presence of primary human BM stroma from normal donors. 




Results represent mean ± SEM of independent experiments using four individual primary 
stromas. Treatment of APL cells with CYP26 inhibitor with or without ATRA in the 
absence of stroma or in the presence of stroma without ATRA had no effect on 























2.4.2    Stromal CYP26 metabolizes atRA 
To prove that stromal CYP26 can metabolize pharmacological levels of atRA, BM 
stroma was incubated with 10
-6
MatRA, and atRA was quantified in the conditioned 
medium by high pressure liquid chromatography—tandem mass spectrometry (HPLC-
MS/MS) (Fig 2A and 2B). In the presence of BM stroma, there is a time dependent 
decrease in atRA levels such that at 24h only about 10% of the atRA remained (p<0.01). 
Inhibition of CYP26 by R115866 blocked the metabolism of atRA such that atRA levels 
were comparable to no stroma controls (p = 0.37) (Fig 2A). Consistent with previous 
reports [34], the elimination half-life of atRA in the absence of stroma was 21.5±1.9h; the 
presence of BM stroma decreased the half-life to only 7.6±0.4h (p<0.01). CYP26 
inhibitor rescued atRA half-life to levels comparable to no stroma control (24.8±3.2h, p = 
















Fig 2.2. Effect of BM stroma on atRA concentrations. Media (RPMI+10%FCS) was 
supplemented with 10
-6
M atRA and incubated at 37°C in a humidified incubator in 
5%CO2 either in the absence of stroma (Control) or in the presence of stroma with or 
without 10-6M CYP26 inhibitor (R115866). A) The concentration of atRA was 
determined at 0h, 2h, 8h and 24h. B) Elimination half-life of atRA (t1/2 = 0.693/slope) 
calculated from the natural logarithms of percent atRA remaining over time. The half-life 
of atRA during culture conditions was 21.5±1.9h in the absence of stroma (Control), 






























2.4.3    BM stroma blocks atRA-induced differentiation of non-APL AML via 
CYP26 
atRA has also been shown to induce differentiation of the t(8;21) core binding factor 
(CBF) AML cell line Kasumi-1[35], although it has shown no clinical activity in CBF 
AML[15–18]. About 20–30% of Kasumi-1 cells exhibit a HSC phenotype (CD34+CD38-) 
(S2 Fig), and culture in the presence of atRA resulted in rapid loss of CD34+CD38- 
compartment both phenotypically and by clonogenic recovery (Fig 3A and 3B, p<0.01). 
Kasumi-1 CD34+CD38- cells and their clonogenic activity were protected from atRA-
induced differentiation when co-cultured with BM stroma (Fig 3A and 3B). This 
protection was rescued by inhibition of CYP26. Again, CYP26 inhibition had no effect in 
stromal-free cultures (data not shown).  
 
While atRA has shown in vitro activity against NPM1-mutated AMLs [35], most studies 
[36, 37] have not confirmed the initial report suggesting clinical activity in this AML 
subtype [13]. Thus, we investigated whether the microenvironment may also play a role 
in these divergent findings regarding the effect of atRA in NPM1-mutated AML. NPM1 
mutated AML cell line OCI-AML3, was treated with atRA in the absence or presence of 
BM stroma (Fig 3D). Treatment of OCI-AML3 cells with 1μMatRA for 72h resulted in 
90% loss of clonogenic growth (p<0.01), while similar treatment in the presence of BM 
stroma had no effect on OCI-AML3 clonogenic recovery. Inhibition of CYP26 by 
R115866 overcame the protective effect of stroma against OCI-AML3 treated with atRA 
(p<0.01). Consistent with the lack of direct cytotoxic effects of ATRA on AML cells, 




















Supplementary Fig 2.2. Flow cytometry analysis of Kasumi-1 cells. Expression of 
CD34 and CD38 prior to sort (upper left plot) and post sort but prior to further culture 
(upper right panel). Middle and lower panels show CD34+CD38- sorted Kasumi-1 cells 
after 72h of culture in the absence (Liquid culture) or presence (Stroma co-culture) of 
BM stroma, respectively. Cells treated with 1μM atRA are presented in middle right 
panel and lower mid panel, and cells treated with 1μM atRA+1μMCYP26 inhibitor, 
R115866 are presented in lower right panel. Dead cells were gated out based on 7AAD 
positivity and non-hematopoietic cells (i.e. BM stroma) were dismissed based on lack of 





Fig 2.3. Effects of bone marrow stroma on atRA-induced differentiation of non-APL 
AML cells. Effects of 10
-6
M atRA ± 10-6M R115866 for 72 hours on (A) the phenotypic 
differentiation and (B) clonogenic growth of Kasumi-1 cells in the presence of OP9 bone 
marrow stroma. CD34+CD38- Kasumi-1 cells were isolated by flow cytometry and 
cultured as described. Data are presented as mean ± SEM of four (A) or three (B) 
independent experiments respectively. C) Effects of 10
-6
M ATRA ± 10-6M R115866 for 
72 hours atRA on the clonogenic growth of OCI/AML-3 cells in the presence of OP9 
bone marrow stroma. Data represent the mean ± SEM of three independent experiments. 




stroma or in the presence of stroma without ATRA had no effect on differentiation status 

























2.4.4    Primary leukemia stem cells (LSCs) are protected from atRA via niche 
CYP26 
Laboratory data suggest that AML maintains the basic hierarchical structure of normal 
hematopoiesis; i.e., rare cells possessing self-renewal capacity, so-called LSCs, give rise 
to partially differentiated progeny that compose the tumor bulk but possess only limited 
proliferative potential [38]. Although the clinical significance of LSCs has been 
questioned, recent data strongly implicate LSCs (CD34+CD38- intermediate ALDH 
activity or ALDHint) in disease relapse; MRD was enriched for LSCs, and their presence 
after therapy highly correlated with subsequent clinical relapse [28]. To test if BM 
microenvironment protects primary LSCs from atRA, we isolated CD34+CD38-ALDH
int
 
cells from the BM of patients with newly-diagnosed CBF [t(8;21)] AML. Prior to culture, 
these cells expressed no differentiation markers such as CD15 (Fig 4A), CD33, and 
CD11b (data not shown). Culture of these cells in media containing 10% serum (and 
about 1nM atRA) [39] led to acquisition of differentiation markers including CD15 (Fig 
4A—upper middle panel). The addition of 1μMatRA induced further up regulation of 
CD15 (Fig 4A; upper right panel, and 4B). Culture in the presence of BM stroma 
inhibited acquisition of CD15 (Fig 4A, lower middle panel, and 4B), and this was rescued 










Fig 2.4. Bone marrow stromal effects on atRA-induced differentiation of primary 
CBF LSCs. (A) One representative experiment (from four independent patients with 
similar results) of CD15 expression of CBF AML CD34+CD38-ALDHint cells prior to 
culture (left upper panel), post 72h of culture in the absence of BM stroma (right upper 
panel), or in the presence of BM stroma (lower panel). Prior to culture, few if any LSCs 




RPMI+10%FCS and thrombopoietin, kit ligand, and Flt3 ligand, a range 8.3%-41.7% of 
cells expressed CD15. (B) Quantitative results from all 4 experiments showing fold 
change of proportion of cells expressing CD15 from control cultures. Data are presented 
as mean ± SEM of fold change from control using CD34+CD38-ALDHint cells from 
four different patients with CBF AML. Treatment of LSCs with CYP26 inhibitor with or 
without ATRA in the absence of stroma or in the presence of stroma without ATRA had 




















2.5     Discussion 
The early success seen with the introduction of atRA in treatment protocols of APL 
raised hope that differentiation therapy could change the face of current treatments in 
leukemia; this was further bolstered by evidence of atRA’s activity against most non-
APL AMLs in vitro [4, 8-12]. Unfortunately, initial enthusiasm has been dampened by 
largely negative results from clinical trials using combination atRA + chemotherapy for 
induction regimens in non-APL AML [16-18]. Nevertheless, preclinical data has shown 
that atRA was actually able to induce terminal differentiation of many subtypes of AML 
in vitro [40]. 
 
Our data suggest that the leukemic microenvironment could provide a potential 
explanation for the lack of clinical benefit of atRA despite in vitro activity, but few if any 
studies have actually focused on the effects of the microenvironment on atRA activity in 
AML. Results presented here show that even the most sensitive AML cells, including 
APL, become resistant to atRA treatment in the presence of stromal CYP26 activity. We 
previously showed that the stem cell niche CYP26 expression also protected normal 
HSCs from retinoids, helping to maintaining them in a quiescent, undifferentiated state 
[25]. Interestingly, since CYP26 is directly up-regulated by retinoids [41] in a variety of 
tissues including hepatocyte, intestine, endothelial cells and even leukemia [42], 
treatment with pharmacological doses of atRA could induce CYP26 expression by the 
BM niche and produce an even more protective microenvironment for LSCs. In-depth 
analysis of CYP26 levels in the BM microenvironment of patients with AML and how 




niche changes in patients with AML. Niche inactivation of atRA could also partially 
explain its ability to induce terminal differentiation of the malignant promyelocytes in 
APL, but the inability to eliminate LSCs. 
 
The relative effectiveness of atRA in APL may result from increased intrinsic sensitivity 
of APL cells comparted to non-APL. The dose of atRA (1M) needed to inhibit non-APL 
cells in the absence of stroma is a log higher than the similar dose (0.1M) active in APL 
cells (Fig 4). Nevertheless, 1M is clinically achieved with therapeutic doses of atRA [43] 
suggesting there are also extrinsic reasons for the lack of effectiveness of atRA in non-
APL AML. Disparities in differentiation status between APL LSCs and non-APL AML 
LSCs [44] may translate into occupancy of distinct niches which could contribute to the 
differential clinical activity seen with ATRA in APL. 
 
Our results reveal therapeutic opportunities for improving the effectiveness of retinoids in 
AML by overcoming the microenvironment’s ability to inactivate atRA. Several CYP26 
inhibitors, including R115866 used here, have safely been in clinical trials for other 
indications such as acne and psoriasis [45]. Systemic inhibition of CYP26 is expected to 
increase plasma atRA levels with potential increased toxicity. Thus, pharmacologically 
adjusting atRA doses to maintain safe systemic concentrations in the presence of CYP26 
inhibition, should control for hepatic inhibition of the enzyme while at the same time 
removing the barrier to therapeutic atRA levels in the microenvironment. The synthetic 
retinoid tamibarotene (AM80) has activity in atRA-resistant APL and is approved in 




responsible for its activity in atRA-resistant APL. Such approaches that circumvent 
CYP26 in the leukemic microenvironment could expand the effectiveness of retinoid-
based therapy in both APL and non-APL AML. 
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3.1   Abstract 
The bone marrow microenvironment contributes to drug resistance in acute myeloid 
leukemia (AML) and multiple myeloma (MM).  We have shown that the critical drug 
metabolizing enzymes cytidine deaminase (CDA) and cytochrome P450 (CYP) 3A4 are 
highly expressed by bone marrow (BM) stroma, and play an important role in AML and 
MM resistance to chemotherapy. However, what factors influence the chemoprotective 
capacity of the BM microenvironment, specifically related to CYP3A4 and CDA 
expression, are unknown. In this study, we found the presence of AML cells decrease 
BM stromal expression of CYP3A4 and CDA, and this effect appears to be at least 
partially the result of cytokines secreted by AML cells. We also observed that stromal 
CYP3A4 expression is upregulated by drugs commonly used in AML induction therapy: 
cytarabine, etoposide, and daunorubicin. In addition, cytarabine also upregulated CDA 
expression. Moreover, the stromal-induced chemoprotection of AML induced by one 
drug cross-reacted to others, and was blocked by clarithromycin, a potent inhibitor of 
CYP3A4. Our data suggest that AML chemotherapy enhances microenviroment-
mediated drug resistance by upregulation of drug metabolizing enzymes. These results 







3.2   Introduction 
Most patients with acute myeloid leukemia (AML) and other hematologic malignancies 
achieve complete remissions (CRs) with initial chemotherapy, but eventually relapse and 
die of their disease [1]. The mechanisms responsible for the resistance of minimal 
residual disease (MRD), the disease remaining in CR that leads to relapse, to therapy are 
also unclear. Emerging data suggest that the cancer stem cell (CSC) concept could 
explain why dramatic responses often fail to translate into cures[2, 3]; this concept 
hypothesizes that relapse in many cancers appears to result from rare cells with stem cell 
characteristics; these so-called CSCs are often biologically distinct from their progeny 
that form the bulk of the tumor, notably exhibiting substantially different sensitivity to 
drugs. In addition to intrinsic mechanisms of drug resistance in MRD, it is now clear that 
specialized microenvironments or niches play important roles in extrinsic drug resistance 
[1, 4-6]. Our group previously showed that bone marrow (BM) stomal cells protect 
normal human hematopoietic stem cells (HSCs) and AML cells from the pro-
differentiating effects of retinoic acid by expressing the retinoid-inactivating enzyme, 
cytochrome P450 (CYP)26 [7, 8]. We also found that stromal CYP3A4 similarly 
protected AML and multiple myeloma (MM) cells from various chemotherapeutic agents 
[9, 10]. However, the exact mechanisms responsible for regulating stromal CYPs are 
unclear.  
 
It is known that the leukemic bone marrow is a pro-inflammatory, cytokine rich 
environment [11] and many of these factors, such as IL6, play important roles in AML 
biology [12-15]. Cytokines and inflammation, especially related to and cancer, have been 
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shown to suppress hepatic and intestinal CYP levels [16-20]. For the initial treatment of 
newly-diagnosed AML patients, the "7+3" regimen, which combine a seven-day 
continuous intravenous infusion of cytarabine (ara-C) (100 or 200 mg/m
2
 per day) with a 
short infusion of an anthracycline given on days one through three, remains the most 
commonly used regimen. Etoposide is another agent used in many induction regimens 
[21, 22]. All three of these agents are substrates for CYP3A4 [23, 24], and ara-C is also 
inactivated by cytidine deaminase (CDA) [25-27]. Chemotherapeutics can induce 
CYP3A4 activity in human liver cells [28]. Thus, the clinical status of the AML and its 
treatment could theoretically influence the expression of CYP3A4 and CDA. 
Accordingly, we hypothesized that effects of tumor burden and chemotherapy on the 
tumor microenvironment could play a role in why complete responses translate into cures 
in only a fraction of patients. In this study, we find that the BM stromal expression of 
CYP3A4 and CDA is influenced by the status of the AML and its treatment, and that 
clinically targeting drug metabolizing enzymes in the microenviroment holds promise. 
 
 
3.3   Materials and Methods 
3.3.1   Cell lines 
The human fetal bone marrow stroma cell line F/STRO was a kind gift from Dr. Pierre 
Marie, and was cultured in DMEM (Gibco, Rockville, MD, USA) with 10% fetal calf 
serum (FCS) (Sigma-Aldrich), 100μg/mL penicillin-streptomycin (Gibco), and 2 mM L-
glutamine (Life Technologies), as previously described[29]. The human AML cell line 
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HL-60 [30] was cultured in RPMI 1640 (Gibco) with 10% FCS, 100μg/mL penicillin-
streptomycin (Gibco), and 2 mM L-glutamine (Life Technologies). The M2 AML cells 
Kasumi-1[31] were cultured in RPMI 1640 + 20% FCS and the NPM1 mutated OCI-
AML3 cells[32] were cultured in minimum essential media (α-MEM) (Corning Cellgro) 
with 20% FCS, 2 mM L-glutamine and 100 μg/mL penicillin-streptomycin.  
 
3.3.2   Isolation of primary bone marrow stroma 
Primary bone marrow stroma cells were derived from normal bone marrow donors 
granting informed consent as approved by the Johns Hopkins Medical Institutes' 
Institutional Review Board, as we have previously described[33]. Briefly, mononuclear 
cells isolated from bone marrow of normal volunteers were cultured in FBMD1 media 
[IMDM media (Gibco) supplemented with 15% FBS (Sigma-Aldrich), 5% Horse serum 
(Sigma-Aldrich), 100μg/mL penicillin-streptomycin (Gibco), and 10
−4
 M β-
mercaptoethanol (Sigma-Aldrich)][34] at 33˚C in 5%CO2 overnight. The next day, media 
and cells in suspension were removed and the attached cells were washed twice with 
phosphate-buffered saline (PBS) (Gibco), fresh FBMD1 media was added to the flask 
and they were placed back 33˚C in 5% CO2. Half of the media was replaced weekly until 
an adherent monolayer has formed. At that time, the cells were dissociated using Trypsin 
(Gibco) and they were either used for further experiments or cryopreserved. The passage 
number of the cells was recorded with original cells labeled as P1. Experiments presented 
in this paper were performed using bone marrow stroma at passages 2-4. 
 
3.3.3   Co-culture system 
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For co-culture conditions, 6-well plates (Sigma) were coated with 0.1% Gelatin (Sigma) 
in PBS for 20 min. at 37˚C. Gelatin solution was removed and stroma cells were seeded 
at a density of 20x10
4
 cells/well and cultured until a confluent monolayer was obtained. 
Subsequently, 2.5x10
4 
HL-60, Kasumi-1, and OCI/AML3 cells were plated per well. The 
cultures were treated with or without 10
-6
M ara-C (Sigma) or 10
-7
M daunorubicin 
(Selleckchem, TX, USA) as well as 10
-6
M etoposide (Sigma) for 72h.  
 
3.3.4   Conditioned medium 
7x10
4  
HL-60, Kasumi-1, and OCI/AML3 cells were cultured under conditions mentioned 
previously for 72h. The cells were centrifuged at 1200rpm for 5min and the supernatant 
was added onto monolayer of FSTRO cells in 6-well plates as previously mentioned.  
 
3.3.5   Chemotherapy drug treatment 
6-well plates (Sigma) were coated with 0.1% Gelatin (Sigma) in PBS for 20 min. at 37˚C. 
Gelatin solution was removed and stroma cells were seeded at a density of 20x10
4
 
cells/well and cultured until a confluent monolayer was obtained. 10
-6
M ara-C (Sigma), 
10
-7
M daunorubicin (Selleckchem), and 10
-6
M VP-16 (Sigma) were added to stroma cells 
for 72h. 
 
3.3.6   Colony forming unit (CFU-C) 
Clonogenic growth of AML cell lines was evaluated as we previously described [35, 36]. 
Briefly, previously treated cells were removed from the plate and washed with PBS to 
remove the respective drug. Cells were then counted using Trypan blue and plated 1 mL 
 75 
1.2% methylcellulose (Sigma-Aldrich), 30% bovine serum albumin (BSA) (Sigma-
Aldrich), 10
-4
 M β-mercaptoethanol (Sigma-Aldrich), and 2 mM L-glutamine (Gibco). 
Samples were plated in duplicate onto 35-mm
2
 tissue culture dishes and incubated in a 
humidified atmosphere at 37°C and 5% CO2. Colonies consisting of more than 40 cells 
were scored at 10-15 days using an inverted microscope.  
 
3.3.7   RNA isolation  
F/STRO and primary BM stroma in culture were dissociated using 0.05% Trypsin (Gibco) 
and collected for total RNA extraction using RNeasy Mini Kit (QIAGEN) following the 
manufacturer’s instructions. For the F/STRO and primary BM stroma co-cultured with 
AML cells, all the cells attached to the plate were dissociated using 0.05% Trypsin 
(Gibco) after the supernatant containing part of the AML cells was washed off. The 
attached cells were re-seeded to the plate and incubated for 30min at 37 °C. Then the 
AML cells in the supernatant were washed off, and the adherent stroma cells were 
harvested using 0.05% Trypsin and used in RNA extraction later using RNeasy Mini kit 
(QIAGEN). The purity of this method separating stroma cells from co-culture is 







Supplementary Figure 3.1. Purity of the method separating stroma cells from co-
culture with AML cells by re-seeding to culture plate for 30 minutes.  
 
Two populations of cells were separated from the co-culture system and showed by Flow 
Cytometry. The red line indicating the HL-60 AML cells taken from the supernatant of 
the co-culture plate. The blue line indication the F/STRO cells isolated by re-seeding all 








3.3.8   Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) 
cDNA was synthesized by reverse transcription using the iScript cDNA synthesis kit 
(BIO-RAD, Hercules, CA). The sequences of the CYP3A4 primers were obtained from 
Integrated DNA Technologies (IDT) at Johns Hopkins Medical Institute DNA Analysis 
Facility, and are as follows: 5′-GCCTGGTGCTCCTCTATCTA-3′ (sense) and 5′-
GGCTGTTGACCATCATAAAAG-3′ (anti-sense). The primers were designed for the 
amplification of a specific CYP3A4 DNA product, which spanned 3 introns of 
the CYP3A4 gene and covers both transcript variant 1 and 2 of CYP3A4. The sequences 
of the CDA primers are as follows: 5′-ATCGCCAGTGACATGCAAGA-3′ (sense) and 
5′-GTACCATCCGGCTTGGTCAT-3′ (anti-sense). GAPDH was used as an endogenous 
control. The primers of GPADH are as follows: 5′-ACCCAGAAGACTGTGGATGG-3′ 
(sense) and 5′- TCTAGACGGCAGGTCAGGTC-3′ (anti-sense). qPCR was performed 
with an Bio-Rad CFX96
TM
 Real-Time PCR Detection System (Bio-Rad, Berkeley, CA) 
and Puregreen lo-ROX qPCR kit (Nextdayscience, Rockville, MD), in accordance with 
the manufacturer’s protocol (a denaturation stage at 95 °C for 2 min; 40 cycles of 5 s at 
95 °C, and 40 cycles of 30 s at 60 °C). 
 
3.3.9   Statistical analysis 
Statistical analysis was performed by using two-tail unpaired student t test to compare the 





3.4   Results 
3.4.1   Active AML generates a CYP3A4 and CDA low environment. 
We previously showed that CYP3A4, other CYPs, and CDA were all highly expressed in 
BM stroma, but not AML and MM cells [9]. To model the BM stroma of AML patients, 
HL-60, Kasumi-1 and OCI-AML3 cells were co-cultured with human normal primary 
BM stroma for 72 hours, and the expression of CYP3A4 and CDA in stroma cells was 
assessed by quantitative reverse transcription PCR (RT-qPCR). All three AML lines 
significantly suppressed the expression of both CYP3A4 and CDA in both primary BM 
stroma (Figure 1A and 1B, respectively) and the human BM stomal line F/STRO (Figure 











Figure 3.1. Effect of AML cells and their culture supernatant to BM MSCs in 
expression of CYP3A4 and CDA 
 
A-B. Relative quantification of CYP3A4 (A) and CDA (B) mRNA expression in F/STRO 
after treatment of medium cultured HL-60, Kasumi-1 and OCI-AML3 for 72 hours. C-D. 
Relative quantification of CYP3A4 (C) and CDA (D) mRNA expression in primary 
human BM MSCs from three different healthy BM donors, after co-cultured with AML 
cell lines HL-60, Kasumi-1 and OCI-AML3 for 72 hours. CYP3A4 and CDA expression 
was normalized to GAPDH, and relative quantification was calculated using ΔΔCT. 
Expression of CYP3A4 and CDA are presented relative to non-treatment control. Results 




3.4.2   Cytokines associated with AML downregulate CYP3A4 and CDA 
It is well-documented that the BM during active AML is a pro-inflammatory environment, 
associated with aberrant cytokine signaling [13, 15]. Moreover, inflammatory cytokines, 
such as IL-1, IL-6 and TNF-α can downregulate hepatic and intestinal CYP3A4 levels 
[18, 19]. Cytokines known to be elevated in AML, IL-1β [37], IL-6 [14], IL-12 [13], 
TNF-α [13, 38], and INF-γ [39] were studied for their ability to modulate CYP3A4 and 
CDA expression in BM stromal cells. After 72 hours of incubation with these cytokines, 
CYP3A4 and CDA mRNA expression was measured in BM stromal cells by RT-qPCR. 
All cytokines tested significantly suppressed the expression of both CYP3A4 and CDA in 
both human BM stomal line F/STRO (Figure 2A and 2B, respectively) and the primary 














Figure 3.2. Effect of cytokines enriched in AML to BM MSCs in expression of 
CYP3A4 and CDA 
 
A-B. Effects of IL-1β, IL-6, IL-12, TNF-α, and IFN-γ (10ng/ml for 72 hrs) on the 
CYP3A4 (A) and CDA (B) mRNA expression in primary human BM MSCs from three 
different healthy BM donors. C-D. Effects of IL-1β, IL-6, IL-12, TNF-α, and IFN-γ 
(10ng/ml for 72 h) on the CYP3A4 (C) and CDA (D) mRNA expression in F/STRO. 





3.4.3   CYP3A4 mRNA expression in human BM stroma cells is upregulated by ara-
C, etoposide, and daunorubicin, while CDA is upregulated only by ara-C 
The most commonly-used chemotherapy drugs for remission induction in AML were 
assessed for the ability to induce the expression drug metabolizing enzymes in BM 
stroma, as they have been reported to do in liver [28]. Ara-C, etoposide, and daunorubicin 
all upregulated CYP3A4 expression of F/STRO stromal cells, while only ara-C 
upregulated CDA (Figure 3A). Similar results were also seen in primary BM stroma 
(Figure 3B). To further confirm the specificity of the drug-induced upregulation, 
CYP26A1 and CYP26B1, enzymes involved in retinoid but not chemotherapy 
inactivation, were measured and found not to be changed significantly upregulated by 














Figure 3.3. Effect of induction chemotherapy drugs in AML to BM MSCs in 
expression of CYP3A4 and CDA 
 
A. Effects of 1µM ara-C, 1µM VP-16, and 0.1µM daunorubicin treatment for 72 hours on 
the mRNA expression levels of CYP3A4 and CDA in F/STRO. B. Effects of 1µM ara-C, 
1µM VP-16, and 0.1µM daunorubicin treatment for 72 hours on the mRNA expression 
levels of CYP3A4 and CDA in primary human BM MSCs from three different healthy 









Supplementary Figure 3.2. Effect of induction chemotherapy drugs in AML to BM 
MSCs in expression of CYP26A1 and CYP26B1 
 
Effects of 1µM ara-C, 1µM VP-16, and 0.1µM daunorubicin treatment for 72 hours on 
the mRNA expression levels of CYP26A1 and CYP26B1 in primary human BM MSCs 











To determine the functional effect of upregulation of drug metabolizing enzymes, the 
effects of drug treatment of BM stroma on AML sensitivity was assessed. AML induction 
chemotherapy is generally given over 7-10 days usually with 2-3 drugs often given 
sequentially[40, 41] Accordingly, F/STRO BM stromal cells were pre-incubated with 
ara-C for 72 hours, and then after removing the drug, co-cultured with two AML cell 
lines (HL-60 and OCI-AML3) with or without etoposide. Preincubation of stomal cells 
with ara-C further protected both the HL-60 cells (Figure 4A) and OCI-AML3 cells 
(Figure 4B) against etoposide. Clarithromycin (Biaxin), a potent CYP3A4 inhibitor [9, 42, 
















Figure 3.4. Role of stromal CYP3A4 in ara-C induced stroma-mediated resistance of 
AML cells to VP-16 treatment 
 
Effects of VP-16 (1 μM for 72 h) on clonogenic activity of HL-60 (A) and OCI-AML3 
(B) AML cells co-cultured with F/STRO BM stroma and ara-C pretreated F/STRO. A. 
Treatment of HL-60 cells co-cultured with wt F/STRO with VP-16 resulted in 47 ± 6%, 
while HL-60 cells co-cultured with ara-C pretreated F/STRO resulted in 65 ± 4% 
clonogenic activity compared to control cultures. Treatment with 1 μM Biaxin reversed 
the protective effect of both wt F/STRO and ara-C pretreated F/STRO to HL-60 cells, 
resulted in 17 ± 3% and 26 ± 4% clonogenic activity, respectively. B. Treatment of OCI-
AML3 cells co-cultured with wt F/STRO with VP-16 resulted in 42 ± 7%, while co-
cultured with ara-C pretreated F/STRO resulted in 64 ± 6% clonogenic activity compared 
to control cultures. Treatment with 1 μM Biaxin reversed the protective effect of both wt 
F/STRO and ara-C pretreated F/STRO to OCI-AML3 cells again VP-16, resulted in 23 ± 
3% and 27 ± 5% clonogenic activity compared to control, respectively. Data are 
presented as mean ± SEM of at least three independent experiments. *p < 0.05. 
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3.5   Discussion 
Previously, our group showed that expression of CYP enzymes appears to be at least 
partly responsible for the well-recognized ability of BM stroma to protect AML and MM 
from chemotherapy [7, 9]. The BM during leukemia therapy is a dynamic environment 
with changes related to treatment and tumor burden, and it is well-established that cancer 
inflammation will modulate CYP expression in the liver [20]. We found that both AML 
cells as well as inflammatory cytokines that are elevated during AML, decrease of 
CYP3A4 and CDA gene expression level in BM stromal, similar to the effect of 
inflammatory cytokines on liver CYP3A4 expression. In addition, we also observed the 
most commonly used drugs for newly-diagnosed AML led to an induction of CYP3A4 
and CDA expression in BM stromal cells. Our findings suggest chemotherapy drug 
metabolizing enzymes in the BM MSCs of AML patients can be modulated by the 
clinical status of bone marrow and chemotherapy drugs, and provide a basis for 
additional studies to address the extent to which these observed changes contribute to 
leukemogenesis or response to treatment.  
 
Accordingly, our data suggest that the induction therapy of AML makes the BM 
microenvironment a more drug resistance one. Along with chemotherapy’s ability to 
induce stroma drug-metabolizing enzymes, the leukemic burden is decreased and the BM 
microenvironment returns to relatively normal state. Overexpression of cytokines in 
leukemia patients declines with remission attainment [14], and our data suggest that both 
the elimination of leukemia and normalization of cytokines should further upregulate 
CYP3A4 and CDA in the BM.  
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These data suggest that the BM microenvironment may plan an important role in the 
relative drug resistance of MRD. Further, our findings suggest a potential role of 
targeting microenvironment drug detoxifying agents in combination with chemotherapy. 
Inhibition of CYP3A4 and CDA in patients at diagnosis and primary refractory disease, 
may render their AML susceptible to chemotherapy. Also, inhibition of CYP3A4 and 
CDA during consolidation therapy, may result in improved elimination of MRD. 
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4.1    Advances in our knowledge of CYP26 in BM microenvironment of 
hematological malignancies 
 
4.1.1     CYP26 alters multiple myeloma microenvironment and generates 
bortezomib resistance 
Since the publication of our work on BM stromal CYP26 caused drug resistance in AML 
(Chapter 2), there had been significant advances in our knowledge of the biology of 
CYP26 in BM microenvironment and CYP26 targeting treatments in hematological 
malignancies. Alonso, S et al [1] in our group has recently shown that an RA-low 
environment induced by stromal CYP26 is responsible for maintaining a B cell–like, 
bortezomib (BTZ) -resistant phenotype in multiple myeloma (MM) cells. Despite being 
broadly studied in many hematological malignancies, the differentiation therapy using 
retinoids has proved beneficial only in patients with APL [2]. Our studies in Chapter 2 
suggest that CYP26 expression by BM stromal cells may explain the lack of a clinical 
benefit of natural retinoids, despite their in vitro activity. Recent studies have highlighted 
the efficacy of CYP-resistant synthetic retinoids in differentiating therapy. For instance, 
AM80 differentiates FMS-like tyrosine kinase 3/internal tandem duplication (FLT3/ITD) 
AML cells and increase their sensitivity to FLT3 inhibitors [3]. Such strategy of  
bypassing stromal CYP26 could expand the clinical effectiveness of retinoid therapy. 
Alonso, S et al proved that directly inhibiting CYP26 or bypassing stromal protection via 
a CYP26-resistant retinoid rescues plasma cells (PCs) differentiation and BTZ sensitivity.  
Furthermore, we described a bidirectional crosstalk, in which paracrine Hedgehog 





stroma to inactivate RA. These data suggested that modulation of RA signaling, such as 
using CYP26-resistant retinoids, is a promising therapeutic strategy for overcoming BTZ 
resistance in the MM BM microenvironment.  
 
4.1.2    Identification of drugs which overcome bone marrow stromal CYP26 in 
AML 
Our group further unveiled the roles of ATRA signaling in the BM microenvironment 
and identified drugs which could overcome bone marrow stromal protection from ATRA 
induced differentiation in APL and non-APL cells. We have found in vitro that the 
synthetic retinoid AM80 [4] and IRX5183 (unpublished data) can overcome the 
protection provided AML cells by CYP26 in bone marrow stroma. AML cell lines from 
APL, NPM1 mutated and core binding factor leukemia (NB4, OCI/AML3, Kasumi 
respectively) were co-cultured with the mouse BM stroma cell line OP-9 and treated with 
ATRA, AM80 or IRX5183. Whereas stroma blocked upregulation of myeloid 
differentiation antigens and caused inhibition of clonogenic activity of AML cells by 
ATRA, both AM80 and IRX5183 induced differentiation in the presence or absence of 
stroma. These data support continued in vitro and in vivo experimentation with CYP 
resistant retinoids. We have developed a phase I clinical trial using IRX5183 in patients 
with relapsed and refractory AML. Given the success of retinoids in APL and their low 
toxicity profile, this may represent a significant advance in the treatment of AML. 
 
In the meanwhile, we tested the impact of RARα and RARγ signaling on stromal CYP26 





and RARβ agonist, IRX5183 is a specific RARα agonist, and ATRA is a pan-RAR 
agonist which was shown to be more selective for RARβ and RARγ with a higher 
binding affinity to these receptors at lower concentrations. By treating OP-9 BM stroma 
cells with these agents in serum free media, we observed that ATRA upregulated 
CYP26B1 at 24 hours followed by a slow drop towards initial level, while AM80 induced 
a constant upregulation of CYP26B1 through 48 hours. IRX5183 only had a modest 
upregulation throughout the 72 hours. Consistent with this, there is no upregulation of 
CYP26B1 in RARγ receptors knockdown human primary stroma, but there is 
upregulation of CYP26B1 in RARα receptor knockdown stroma. Even after 24 hours of 
ATRA treatment there is mainly upregulation of CYP26B1 in the RARα KD model. 
These results suggest that the activation of RARα is able to differentiate leukemia cells, 
while RARγ is dispensable for differentiation; and that the activation of RARγ causes up 
regulation of CYP26B1 and creates a more protective microenvironment (unpublished 
data).  
 
4.2    Advances in our knowledge of CYP3A4 in BM microenvironment of 
hematological malignancies and drug resistance 
 
4.2.1    CYP3A4 mediated chemoprotection in BM microenvironment of multiple 
myeloma and AML 
Our initial studies [5, 6] demonstrated that normal and malignant stem cells are protected 
from the pro-differentiating effects of RA by BM microenvironment via CYP26. It is 





any chemotherapy agent used in the clinic. Based on this, we proposed that the BM niche 
protects malignant cells from chemotherapy via drug inactivation. In despite the efficacy 
of chemotherapy to eliminate leukemic cells from the peripheral circulation, they survive 
within the BM niche, contributing to MRD and relapse.  Indeed, the vast majority of 
detoxifying enzymes of the P450 superfamily are highly expressed by the BM niche at 
comparable levels to human hepatocytes [7]. Non-P450 metabolizing enzymes are also 
expressed in BM stroma, including cytidine deaminase. In contrast, expression of 
detoxifying enzymes within hematopoietic compartment is minimal.  
 
As mentioned in Chapter 1, CYP3A4 is the most important P450 enzyme in the liver and 
is also expressed in the BM niche [8]. CYP3A4 metabolizes over 50% of therapeutic 
drugs, including bortezomib, used in in the treatment of MM. Despite achieving 
significant responses in patients, bortezomib does not completely eradicate MM cells 
from the BM. For this reason, we evaluated the role of stromal CYP3A4 on bortezomib 
resistance. Despite being highly sensitive to bortezomib, MM cells become resistant in 
the presence of BM mesenchymal cells. However, inhibition of stromal CYP3A4 by 
ketoconazole, or shRNA-mediated knockdown, rescues sensitivity to bortezomib [7]. 
This suggests that inactivation by the BM niche is at least partially responsible for 
bortezomib resistance in multiple myeloma.   
 
Dexamethasone is another CYP3A4 target used in the treatment of MM, often in 
combination with lenalidomide, as part of the Rev/Dex (Revlimid®, dexamethasone) 





clarithromycin (used in Chapter 3), a potent CYP3A4 inhibitor, in patients with 
respiratory infections, potentiated multiple myeloma treatment. Subsequent studies 
dismissed any activity of clarithromycin as single-agent, but confirmed its clinical benefit 
when combined with dexamethasone [10, 11]. Moreover, even patients refractory to high 
dose dexamethasone or Rev/Dex respond to the addition of clarithromycin [12]. While 
different mechanisms of action against multiple myeloma have been proposed [13-15]. 
We showed that clarithromycin disrupts the BM niche barriers for drug delivery. 
Consistent with this, inhibition of CYP3A4 by clarithromycin or shRNA-mediated 
knockdown, restores dexamethasone concentration in stromal conditioned media, and 
overcomes stromal protection of MM cells against dexamethasone [7]. Furthermore, 
clarithromycin has no effect on dexamethasone’s activity in the absence of BM 
mesenchymal cells, suggesting that it exclusively targets the bone marrow niche.   
 
To extend these findings to other hematological malignancies, we examined the role of 
stromal CYP3A4 on AML resistance against etoposide (VP-16). Analogous to 
bortezomib treatment of multiple myeloma cells, AML blasts become refractory to 
etoposide treatment in the presence of BM mesenchymal cells, unless etoposide 
inactivation is prevented via CYP3A4 inhibition or knockdown [7]. Moreover, 
xenografted AML tumors containing wild-type BM mesenchymal cells are refractory to 
etoposide treatment, evidenced by continued exponential growth. However, tumors 
containing BM mesenchymal cells with CYP3A4 knockdown exhibit a sustained 
response to etoposide. This further confirms the role of the BM niche in regulating local 






4.2.1    CYP3A4 mediated chemoprotection in BM microenvironment of FLT3-AML 
 
After our aforementioned discoveries of drug resistance mechanism mediated by CYP26 
and CYP3A4 in BM microenvironment of AML and MM, we further explore whether 
CYP3A4 contributes to bone marrow mediated FLT3-AML protection from FLT3 
inhibitors.  
 
FLT3-AML takes approximately 1/3 of AML patients, and is associate with worse 
prognosis, higher relapse rate, and lower survival rate. It is characterized by mutations in 
FLT3 gene in leukemic cells, which is a promising target to treat FLT3-AML. In clinical 
trials, patients treated with FLT3 inhibitors show excellent clearance of peripheral blasts. 
However, the effect is minor in bone marrow, resulting in failure of leukemia eradication. 
Therefore, we hypothesize that stromal CYP3A4, by inactivating FLT3 inhibitors, 
contributes to bone marrow-mediated FLT3-AML protection from FLT3 inhibitors. 
Using colony formatting units (CFU) assay, we found that when co-culture FLT3-AML 
and BM MSCs with FLT3 inhibitor treatment, both knocking down CYP3A4 in MSCs 
and adding clarithromycin (a CYP3A4 inhibitor) repealed the protection effect of stroma. 
In mouse xenograft model, knocking down stromal CYP3A4 significantly restored the 
sensitivity of FLT3-AML tumors to the FLT3 inhibitor. Furthermore, measured by liquid 
chromatography-tandem mass spectrometry, the concentration of the FLT3 inhibitor in 
BM stroma culture media decreased in a time-dependent manner, whereas no decrease 





data revealed a drug resistance mechanism mediated by CYP3A4 and CYP3A4 in BM 
microenvironment of FLT3-AML. By metabolizing FLT3 inhibitors, stromal CYP3A4 
creates an environment with lower FLT3 inhibitor concentration which is inefficient for 
leukemic growth inhibition. Combining FLT3 inhibitors with drug-metabolizing enzyme 
inhibitors may become a promising strategy to overcome drug resistance against FLT3-
AML. Our results provide new insights to understanding bone marrow niche-derived 
drug resistance in hematological malignancies.  
 
4.3    Advances in targeting stem cells clinically in AML 
Indeed, since the increasing evidences of leukemia stem cells (LSCs) are responsible for 
recurrence and therapeutic resistance [16-19], targeting LSCs is becoming an attractive 
therapeutic strategy. There are finished or in progress studies using monoclonal antibody 
therapy targeting CD33+ cells [20-22], CLL-1+ cells [23], and CD123+ cells [24, 25] on 
AML patients. In addition to directly targeting stem cells in consider of their cell-intrinsic 
mechanism, studies targeting the LSCs niche to attenuate their cell-extrinsic protection to 
the LSCs are also ongoing. There has been a clinical trial for inhibition of 
CXCR4/CXL12 axis in relapsed and refractory AML [26]. Other adhesion molecules 
such as CD44 [27] and V-CAM [28] have also been targeted to overcome the 
microenvironment-mediated drug resistance in AML. Based on our discoveries of 
detoxifying effects of CYPs in the microenvironment [6, 7], our group have developed 
several clinical trials aimed at overcoming this potential mechanism for LSC resistance. 
The heterogeneity, clinical significance and clinical targets of LSCs has been nicely 






4.4    Concluding remarks 
Current strategies to overcome niche-mediated chemo-protection are majorly aimed at 
mobilizing malignant cells from their niche, by targeting adhesion molecules or 
chemokines. Pre-clinical studies have shown promising results of such strategies; 
however, this has not translated in increased patient cures. Furthermore, these approaches 
have not fully explain the niche enigma, and as a consequence, are unable to target the 
root cause of the problem: cancer stem cells within the BM niche. 
 
We have investigated a novel mechanism in which cytochrome P450 enzymes in the BM 
niche produce a drug-free sanctuary by inactivating retinoic acid and chemotherapy 
agents, protecting normal and malignant stem cells. We have also found the factors 
influence the chemoprotective capacity of the BMT microenvironment, including 
presence of AML cells and the cytokines secreted by AML cells, and treatment of 
chemotherapy drugs which commonly used in AML induction therapy. Our findings  
suggest a potential role for clinically targeting drug metabolizing enzymes in the BM 
microenviroment. Targeting these drug metabolizing enzymes, while adjusting 
pharmacologic doses to maintain safe systemic concentrations, should disrupt these 
sanctuaries and target cancer cells within their microenvironment, with the ultimate goal 
of increasing cures in hematologic malignancies. 
 
Cancer is a devastating disease, and AML is one of the deadliest malignant tumors, with 





for AML patients is still a major barrier to the long-term survival of these patients. While 
5-year survival is still relatively low, it is important to make progress in the development 
of new agents and hopefully eliminate minimal residual disease. With continued research 
and identification of novel therapeutic targets, improved clinical regiment and clinical 
care, AML might one day become a more manageable malignancy like many breast 
cancers and prostate cancers now are. 
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